Atrasentan in Patients With Proteinuric Glomerular Diseases

Clinical trial NCT04573920 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04573920
Sponsor: Novartis Pharmaceuticals
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

IgA Nephropathy Focal Segmental Glomerulosclerosis Alport Syndrome Diabetic Kidney Disease Diabetic Nephropathy Type 2 Immunoglobulin A Nephropathy

Start date: 2021-03-15
Primary completion: 2024-07-02
Enrollment: 103

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.